|
1
|
GBD 2019 Diseases and Injuries
Collaborators, . Global burden of 369 diseases and injuries in 204
countries and territories, 1990–2019: A systematic analysis for the
Global Burden of Disease Study 2019. Lancet. 396:1204–1222. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xia C, Dong X, Li H, Cao M, Sun D, He S,
Yang F, Yan X, Zhang S, Li N and Chen W: Cancer statistics in China
and United States, 2022: Profiles, trends, and determinants. Chin
Med J (Engl). 135:584–590. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Qiu H, Cao S and Xu R: Cancer incidence,
mortality, and burden in China: A time-trend analysis and
comparison with the United States and United Kingdom based on the
global epidemiological data released in 2020. Cancer Commun (Lond).
41:1037–1048. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agirre E and Eyras E: Databases and
resources for human small non-coding RNAs. Hum Genomics. 5:192–199.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee JT: Epigenetic regulation by long
noncoding RNAs. Science. 338:1435–1439. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Takahashi A, Tsutsumi R, Kikuchi I, Obuse
C, Saito Y, Seidi A, Karisch R, Fernandez M, Cho T, Ohnishi N, et
al: SHP2 tyrosine phosphatase converts parafibromin/Cdc73 from a
tumor suppressor to an oncogenic driver. Mol Cell. 43:45–56. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Statello L, Guo CJ, Chen LL and Huarte M:
Gene regulation by long non-coding RNAs and its biological
functions. Nat Rev Mol Cell Bio. 22:96–118. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hua Q, Mi B, Xu F, Wen J, Zhao L, Liu J
and Huang G: Hypoxia-induced lncRNA-AC020978 promotes proliferation
and glycolytic metabolism of non-small cell lung cancer by
regulating PKM2/HIF-1α axis. Theranostics. 10:4762–4778. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Yu Y, Li H, Hu Q, Chen X, He Y,
Xue C, Ren F, Ren Z, Li J, et al: Long non-coding RNA PVT1 promotes
tumor progression by regulating the miR-143/HK2 axis in gallbladder
cancer. Mol Cancer. 18:332019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Devaux Y, Zangrando J, Schroen B, Creemers
EE, Pedrazzini T, Chang CP, Dorn GN, Thum T II and Heymans S;
Cardiolinc network, : Long noncoding RNAs in cardiac development
and ageing. Nat Rev Cardiol. 12:415–425. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Magistri M, Faghihi MA, St Laurent G III
and Wahlestedt C: Regulation of chromatin structure by long
noncoding RNAs: Focus on natural antisense transcripts. Trends
Genet. 28:389–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui XY, Zhan JK and Liu YS: Roles and
functions of antisense lncRNA in vascular aging. Ageing Res Rev.
72:1014802021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bian Z, Zhang J, Li M, Feng Y, Wang X,
Zhang J, Yao S, Jin G, Du J, Han W, et al: LncRNA-FEZF1-AS1
promotes tumor proliferation and metastasis in colorectal cancer by
regulating PKM2 Signaling. Clin Cancer Res. 24:4808–4819. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang MH, Zhao L, Wang L, Ou-Yang W, Hu SS,
Li WL, Ai ML, Wang YQ, Han Y, Li TT, et al: Nuclear lncRNA HOXD-AS1
suppresses colorectal carcinoma growth and metastasis via
inhibiting HOXD3-induced integrin β3 transcriptional activating and
MAPK/AKT signalling. Mol Cancer. 18:312019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Braga EA, Fridman MV, Moscovtsev AA,
Filippova EA, Dmitriev AA and Kushlinskii NE: LncRNAs in ovarian
cancer progression, metastasis, and main pathways: ceRNA and
alternative mechanisms. Int J Mol Sci. 21:88552020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pan H, Ding Y, Jiang Y, Wang X, Rao J,
Zhang X, Yu H, Hou Q and Li T: LncRNA LIFR-AS1 promotes
proliferation and invasion of gastric cancer cell via
miR-29a-3p/COL1A2 axis. Cancer Cell Int. 21:72021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Si Z, Yu L, Jing H, Wu L and Wang X:
Oncogenic lncRNA ZNF561-AS1 is essential for colorectal cancer
proliferation and survival through regulation of
miR-26a-3p/miR-128-5p-SRSF6 axis. J Exp Clin Canc Res. 40:782021.
View Article : Google Scholar
|
|
22
|
Shuai Y, Ma Z, Liu W, Yu T, Yan C, Jiang
H, Tian S, Xu T and Shu Y: TEAD4 modulated LncRNA MNX1-AS1
contributes to gastric cancer progression partly through
suppressing BTG2 and activating BCL2. Mol Cancer. 19:62020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yao W, Du X, Zhang J, Wang Y, Wang M, Pan
Z and Li Q: SMAD4-induced knockdown of the antisense long noncoding
RNA BRE-AS contributes to granulosa cell apoptosis. Mol Ther
Nucleic Acids. 25:251–263. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang B, Yuan Y, Yi T and Dang W: The
roles of antisense long noncoding RNAs in tumorigenesis and
development through Cis-Regulation of neighbouring genes.
Biomolecules. 13:6842023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu B, Xiang W and Liu J, Tang J, Wang J,
Liu B, Long Z, Wang L, Yin G and Liu J: The regulatory role of
antisense lncRNAs in cancer. Cancer Cell Int. 21:4592021.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li D, Shen L, Zhang X, Chen Z, Huang P,
Huang C and Qin S: LncRNA ELF3-AS1 inhibits gastric cancer by
forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA
stability via interacting with ILF2/ILF3 complex. J Exp Clin Cancer
Res. 41:3322022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bartl J, Zanini M, Bernardi F, Forget A,
Blumel L, Talbot J, Picard D, Qin N, Cancila G, Gao Q, et al: The
HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of
dynein complex 1 in human SHH-driven tumors. Nat Commun.
13:40612022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jadaliha M, Gholamalamdari O, Tang W,
Zhang Y, Petracovici A, Hao Q, Tariq A, Kim TG, Holton SE, Singh
DK, et al: A natural antisense lncRNA controls breast cancer
progression by promoting tumor suppressor gene mRNA stability. PLoS
Genet. 14:e10078022018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pan K and Xie Y: LncRNA FOXC2-AS1 enhances
FOXC2 mRNA stability to promote colorectal cancer progression via
activation of Ca(2+)-FAK signal pathway. Cell Death Dis.
11:4342020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhao Y, Liu Y, Lin L, Huang Q, He W, Zhang
S, Dong S, Wen Z, Rao J, Liao W and Shi M: The lncRNA MACC1-AS1
promotes gastric cancer cell metabolic plasticity via AMPK/Lin28
mediated mRNA stability of MACC1. Mol Cancer. 17:692018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tsai MC, Manor O, Wan Y, Mosammaparast N,
Wang JK, Lan F, Shi Y, Segal E and Chang HY: Long noncoding RNA as
modular scaffold of histone modification complexes. Science.
329:689–693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhu L, Zhu Y, Han S, Chen M, Song P, Dai
D, Xu W, Jiang T, Feng L, Shin VY, et al: Impaired autophagic
degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in
gastric cancer. Cell Death Dis. 10:3832019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Visvanathan A, Patil V, Arora A, Hegde AS,
Arivazhagan A, Santosh V and Somasundaram K: Essential role of
METTL3-mediated m(6)A modification in glioma stem-like cells
maintenance and radioresistance. Oncogene. 37:522–533. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tran NT, Su H, Khodadadi Jamayran A, Lin
S, Zhang L, Zhou D, Pawlik KM, Townes TM, Chen Y, Mulloy JC and
Zhao X: The AS-RBM15 lncRNA enhances RBM15 protein translation
during megakaryocyte differentiation. EMBO Rep. 17:887–900. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang J and Manley JL: Misregulation of
pre-mRNA alternative splicing in cancer. Cancer Discov.
3:1228–1237. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Oltean S and Bates DO: Hallmarks of
alternative splicing in cancer. Oncogene. 33:5311–5318. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yuan JH, Liu XN, Wang TT, Pan W, Tao QF,
Zhou WP, Wang F and Sun SH: The MBNL3 splicing factor promotes
hepatocellular carcinoma by increasing PXN expression through the
alternative splicing of lncRNA-PXN-AS1. Nat Cell Biol. 19:820–832.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhou M, Guo X, Wang M and Qin R: The
patterns of antisense long non-coding RNAs regulating corresponding
sense genes in human cancers. J Cancer. 12:1499–1506. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Luo N, Zhang K, Li X and Hu Y: ZEB1
induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the
progression of triple negative breast cancer by binding with ELAVL1
to maintain the stability of ZEB1 mRNA. J Cell Biochem.
121:4176–4187. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang A, Bao Y, Wu Z, Zhao T, Wang D, Shi
J, Liu B, Sun S, Yang F, Wang L and Qu L: Long noncoding RNA
EGFR-AS1 promotes cell growth and metastasis via affecting HuR
mediated mRNA stability of EGFR in renal cancer. Cell Death Dis.
10:1542019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gong YQ, Lu TL, Hou FT and Chen CW:
Antisense long non-coding RNAs in gastric cancer. Clin Chim Acta.
534:128–137. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Su J, Chen D, Ruan Y, Tian Y, Lv K, Zhou
X, Ying D and Lu Y: LncRNA MBNL1-AS1 represses gastric cancer
progression via the TGF-β pathway by modulating miR-424-5p/Smad7
axis. Bioengineered. 13:6978–6995. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zhuang L, Ding W, Ding W, Zhang Q, Xu X
and Xi D: lncRNA ZNF667-AS1 (NR_036521.1) inhibits the progression
of colorectal cancer via regulating ANK2/JAK2 expression. J Cell
Physiol. 236:2178–2193. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sun M, Nie F, Wang Y, Zhang Z, Hou J, He
D, Xie M, Xu L, De W, Wang Z and Wang J: LncRNA HOXA11-AS promotes
proliferation and invasion of gastric cancer by scaffolding the
chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res.
76:6299–6310. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Lin X, Zhuang S, Chen X, Du J, Zhong L,
Ding J, Wang L, Yi J, Hu G, Tang G, et al: lncRNA ITGB8-AS1
functions as a ceRNA to promote colorectal cancer growth and
migration through integrin-mediated focal adhesion signaling. Mol
Ther. 30:688–702. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bedoui S, Herold MJ and Strasser A:
Emerging connectivity of programmed cell death pathways and its
physiological implications. Nat Rev Mol Cell Bio. 21:678–695. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu J, Hong M, Li Y, Chen D, Wu Y and Hu
Y: Programmed cell death tunes tumor immunity. Front Immunol.
13:8473452022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng C, Chu M, Chen Q, Chen C, Wang ZW
and Chen X: The role of lncRNA OIP5-AS1 in cancer development and
progression. Apoptosis. 27:311–321. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang Z and Jin J: LncRNA SLCO4A1-AS1
promotes colorectal cancer cell proliferation by enhancing
autophagy via miR-508-3p/PARD3 axis. Aging (Albany NY).
11:4876–4889. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xia X, Wang X, Cheng Z, Qin W, Lei L,
Jiang J and Hu J: The role of pyroptosis in cancer: Pro-cancer or
pro-‘host’? Cell Death Dis. 10:6502019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Huang G, Xiang Z, Wu H, He Q, Dou R, Lin
Z, Yang C, Huang S, Song J, Di Z, et al: The lncRNA
BDNF-AS/WDR5/FBXW7 axis mediates ferroptosis in gastric cancer
peritoneal metastasis by regulating VDAC3 ubiquitination. Int J
Biol Sci. 18:1415–1433. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bai Y and Li S: Long noncoding RNA
OIP5-AS1 aggravates cell proliferation, migration in gastric cancer
by epigenetically silencing NLRP6 expression via binding EZH2. J
Cell Biochem. 121:353–362. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang LW, Li XB, Liu Z, Zhao LH, Wang Y and
Yue L: Long non-coding RNA OIP5-AS1 promotes proliferation of
gastric cancer cells by targeting miR-641. Eur Rev Med Pharmacol
Sci. 23:10776–10784. 2019.PubMed/NCBI
|
|
54
|
Tao Y, Wan X, Fan Q, Wang Y, Sun H, Ma L,
Sun C and Wu Y: Long non-coding RNA OIP5-AS1 promotes the growth of
gastric cancer through the miR-367-3p/HMGA2 axis. Dig Liver Dis.
52:773–779. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liao Y, Zhang B, Zhang T, Zhang Y and Wang
F: LncRNA GATA6-AS promotes cancer cell proliferation and inhibits
apoptosis in glioma by downregulating lncRNA TUG1. Cancer Biother
Radiopharm. 34:660–665. 2019.PubMed/NCBI
|
|
56
|
Russell RC and Guan KL: The multifaceted
role of autophagy in cancer. EMBO J. 41:e1100312022. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Li X, He S and Ma B: Autophagy and
autophagy-related proteins in cancer. Mol cancer. 19:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Li J, Zhan H, Ren Y, Feng M, Wang Q, Jiao
Q, Wang Y, Liu X, Zhang S, Du L, et al: Sirtuin 4 activates
autophagy and inhibits tumorigenesis by upregulating the p53
signaling pathway. Cell Death Differ. 30:313–326. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Feng X, Zhang H, Meng L, Song H, Zhou Q,
Qu C, Zhao P, Li Q, Zou C, Liu X and Zhang Z: Hypoxia-induced
acetylation of PAK1 enhances autophagy and promotes brain
tumorigenesis via phosphorylating ATG5. Autophagy. 17:723–742.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Elias EE, Lyons B and Muruve DA:
Gasdermins and pyroptosis in the kidney. Nat Rev Nephrol.
19:337–350. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wei X, Xie F, Zhou X, Wu Y, Yan H, Liu T,
Huang J, Wang F, Zhou F and Zhang L: Role of pyroptosis in
inflammation and cancer. Cell Mol Immunol. 19:971–992. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tang R, Xu J, Zhang B, Liu J, Liang C, Hua
J, Meng Q, Yu X and Shi S: Ferroptosis, necroptosis, and pyroptosis
in anticancer immunity. J Hematol Oncol. 13:1102020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang P, Yang W, Wei Z, Li Y, Yang Y and
Wang J: Novel targets for gastric cancer: The tumor
microenvironment (TME), N6-methyladenosine (m6A), pyroptosis,
autophagy, ferroptosis and cuproptosis. Biomed Pharmacother.
163:1148832023. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang Z, Cao L, Zhou S, Lyu J, Gao Y and
Yang R: Construction and validation of a novel pyroptosis-related
Four-lncRNA prognostic signature related to gastric cancer and
immune infiltration. Front Immunol. 13:8547852022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ren N, Jiang T, Wang C, Xie S, Xing Y,
Piao D, Zhang T and Zhu Y: LncRNA ADAMTS9-AS2 inhibits gastric
cancer (GC) development and sensitizes chemoresistant GC cells to
cisplatin by regulating miR-223-3p/NLRP3 axis. Aging (Albany NY).
12:11025–11041. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Tang D, Chen X, Kang R and Kroemer G:
Ferroptosis: Molecular mechanisms and health implications. Cell
Res. 31:107–125. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Wu Y, Zhang S, Gong X, Tam S, Xiao D, Liu
S and Tao Y: The epigenetic regulators and metabolic changes in
ferroptosis-associated cancer progression. Mol Cancer. 19:392020.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Katada S, Imhof A and Sassone-Corsi P:
Connecting threads: Epigenetics and metabolism. Cell. 148:24–28.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Ganapathy-Kanniappan S and Geschwind JF:
Tumor glycolysis as a target for cancer therapy: Progress and
prospects. Mol Cancer. 12:1522013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Vaupel P, Schmidberger H and Mayer A: The
Warburg effect: Essential part of metabolic reprogramming and
central contributor to cancer progression. Int J Radiat Biol.
95:912–919. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Liberti MV and Locasale JW: The warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li C, Wang P, Du J, Chen J, Liu W and Ye
K: LncRNA RAD51-AS1/miR-29b/c-3p/NDRG2 crosstalk repressed
proliferation, invasion and glycolysis of colorectal cancer. IUBMB
life. 73:286–298. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Cheng X, Li J and Guo D: SCAP/SREBPs are
central players in lipid metabolism and novel metabolic targets in
cancer therapy. Curr Top Med Chem. 18:484–493. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Li C, Zhang L, Qiu Z, Deng W and Wang W:
Key molecules of fatty acid metabolism in gastric cancer.
Biomolecules. 12:7062022. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gong J, Lin Y, Zhang H, Liu C, Cheng Z,
Yang X, Zhang J, Xiao Y, Sang N, Qian X, et al: Reprogramming of
lipid metabolism in cancer-associated fibroblasts potentiates
migration of colorectal cancer cells. Cell Death Dis. 11:2672020.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Guo D, Reinitz F, Youssef M, Hong C,
Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, et al:
An LXR agonist promotes glioblastoma cell death through inhibition
of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov.
1:442–456. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang J, Song F, Zhao X, Jiang H, Wu X,
Wang B, Zhou M, Tian M, Shi B, Wang H, et al: EGFR modulates
monounsaturated fatty acid synthesis through phosphorylation of
SCD1 in lung cancer. Mol Cancer. 16:1272017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Tang Y, Tang R, Tang M, Huang P, Liao Z,
Zhou J, Zhou L, Su M, Chen P, Jiang J, et al: LncRNA DNAJC3-AS1
Regulates fatty acid synthase via the EGFR pathway to promote the
progression of colorectal cancer. Front Oncol. 10:6045342020.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Currie E, Schulze A, Zechner R, Walther TC
and Farese RJ: Cellular fatty acid metabolism and cancer. Cell
Metab. 18:153–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Carracedo A, Cantley LC and Pandolfi PP:
Cancer metabolism: Fatty acid oxidation in the limelight. Nat Rev
Cancer. 13:227–232. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
He W, Liang B, Wang C, Li S, Zhao Y, Huang
Q, Liu Z, Yao Z, Wu Q, Liao W, et al: MSC-regulated lncRNA
MACC1-AS1 promotes stemness and chemoresistance through fatty acid
oxidation in gastric cancer. Oncogene. 38:4637–4654. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Greten FR and Grivennikov SI: Inflammation
and cancer: Triggers, mechanisms, and consequences. Immunity.
51:27–41. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Nie C, Zhai J, Wang Q, Zhu X, Xiang G, Liu
C, Liu T, Wang W, Wang Y, Zhao Y, et al: Comprehensive analysis of
an individualized Immune-Related lncRNA pair signature in gastric
cancer. Front Cell Dev Biol. 10:8056232022. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Cui X, Morales RT, Qian W, Wang H, Gagner
JP, Dolgalev I, Placantonakis D, Zagzag D, Cimmino L, Snuderl M, et
al: Hacking macrophage-associated immunosuppression for regulating
glioblastoma angiogenesis. Biomaterials. 161:164–178. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wang H, Tian T and Zhang J:
Tumor-Associated Macrophages (TAMs) in Colorectal Cancer (CRC):
From mechanism to therapy and prognosis. Int J Mol Sci.
22:84702021. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lazăr DC, Avram MF, Romoșan I, Cornianu M,
Tăban S and Goldiș A: Prognostic significance of tumor immune
microenvironment and immunotherapy: Novel insights and future
perspectives in gastric cancer. World J Gastroenterol.
24:3583–3616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Denaro N, Merlano MC and Lo Nigro C: Long
noncoding RNAs as regulators of cancer immunity. Mol Oncol.
13:61–73. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Xu M, Xu X, Pan B, Chen X, Lin K, Zeng K,
Liu X, Xu T, Sun L, Qin J, et al: LncRNA SATB2-AS1 inhibits tumor
metastasis and affects the tumor immune cell microenvironment in
colorectal cancer by regulating SATB2. Mol Cancer. 18:1352019.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Sanchez-Tillo E, Liu Y, de Barrios O,
Siles L, Fanlo L, Cuatrecasas M, Darling DS, Dean DC, Castells A
and Postigo A: EMT-activating transcription factors in cancer:
Beyond EMT and tumor invasiveness. Cell Mol Life Sci. 69:3429–3456.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Dongre A and Weinberg RA: New insights
into the mechanisms of epithelial-mesenchymal transition and
implications for cancer. Nat Rev Mol Cell Bio. 20:69–84. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Song Y, Lin M, Liu Y, Wang ZW and Zhu X:
Emerging role of F-box proteins in the regulation of
epithelial-mesenchymal transition and stem cells in human cancers.
Stem Cell Res Ther. 10:1242019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Brabletz S, Schuhwerk H, Brabletz T and
Stemmler MP: Dynamic EMT: A multi-tool for tumor progression. EMBO
J. 40:e1086472021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Lin J, Shi Z, Yu Z and He Z: LncRNA
HIF1A-AS2 positively affects the progression and EMT formation of
colorectal cancer through regulating miR-129-5p and DNMT3A. Biomed
Pharmacother. 98:433–439. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yu J, Han Z, Sun Z, Wang Y, Zheng M and
Song C: LncRNA SLCO4A1-AS1 facilitates growth and metastasis of
colorectal cancer through β-catenin-dependent Wnt pathway. J Exp
Clin Canc Res. 37:2222018. View Article : Google Scholar
|
|
98
|
Zhou L, Jiang J, Huang Z, Jin P, Peng L,
Luo M, Zhang Z, Chen Y, Xie N, Gao W, et al: Hypoxia-induced lncRNA
STEAP3-AS1 activates Wnt/β-catenin signaling to promote colorectal
cancer progression by preventing m(6)A-mediated degradation of
STEAP3 mRNA. Mol Cancer. 21:1682022. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Ali MM, Akhade VS, Kosalai ST, Subhash S,
Statello L, Meryet-Figuiere M, Abrahamsson J, Mondal T and Kanduri
C: PAN-cancer analysis of S-phase enriched lncRNAs identifies
oncogenic drivers and biomarkers. Nat Commun. 9:8832018. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Mo S, Zhang L, Dai W, Han L, Wang R, Xiang
W, Wang Z, Li Q, Yu J, Yuan J, et al: Antisense lncRNA LDLRAD4-AS1
promotes metastasis by decreasing the expression of LDLRAD4 and
predicts a poor prognosis in colorectal cancer. Cell Death Dis.
11:1552020. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Slattery ML, Herrick J, Curtin K, Samowitz
W, Wolff RK, Caan BJ, Duggan D, Potter JD and Peters U: Increased
risk of colon cancer associated with a genetic polymorphism of
SMAD7. Cancer Res. 70:1479–1485. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Rakic JM, Maillard C, Jost M, Bajou K,
Masson V, Devy L, Lambert V, Foidart JM and Noel A: Role of
plasminogen activator-plasmin system in tumor angiogenesis. Cell
Mol Life Sci. 60:463–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Bajou K, Maillard C, Jost M, Lijnen RH,
Gils A, Declerck P, Carmeliet P, Foidart JM and Noel A:
Host-derived plasminogen activator inhibitor-1 (PAI-1)
concentration is critical for in vivo tumoral angiogenesis and
growth. Oncogene. 23:6986–6990. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Teng F, Zhang JX, Chen Y, Shen XD, Su C,
Guo YJ, Wang PH, Shi CC, Lei M, Cao YO and Liu SQ: LncRNA
NKX2-1-AS1 promotes tumor progression and angiogenesis via
upregulation of SERPINE1 expression and activation of the VEGFR-2
signaling pathway in gastric cancer. Mol Oncol. 15:1234–1255. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Duan S, Huang W, Liu X, Liu X, Chen N, Xu
Q, Hu Y, Song W and Zhou J: IMPDH2 promotes colorectal cancer
progression through activation of the PI3K/AKT/mTOR and
PI3K/AKT/FOXO1 signaling pathways. J Exp Clin Canc Res. 37:3042018.
View Article : Google Scholar
|
|
107
|
Peng Y, Wang Y, Zhou C, Mei W and Zeng C:
PI3K/Akt/mTOR pathway and its role in cancer therapeutics: Are we
making headway? Front Oncol. 12:8191282022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Liu HT, Ma RR, Lv BB, Zhang H, Shi DB, Guo
XY, Zhang GH and Gao P: LncRNA-HNF1A-AS1 functions as a competing
endogenous RNA to activate PI3K/AKT signalling pathway by sponging
miR-30b-3p in gastric cancer. Br J Cancer. 122:1825–1836. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Guo C, Zhou S, Yi W, Yang P, Li O, Liu J
and Peng C: Long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS)
is a potential diagnostic and prognostic biomarker and therapeutic
target for hepatocellular carcinoma. Exp Mol Pathol.
120:1046382021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
El-Ashmawy NE, Al-Ashmawy GM and Hamouda
SM: Long non-coding RNA FAM83H-AS1 as an emerging marker for
diagnosis, prognosis and therapeutic targeting of cancer. Cell
Biochem Funct. 39:350–356. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Da J, Liu P, Wang R and Bu L: Upregulation
of the long non-coding RNA FAM83H-AS1 in gastric cancer and its
clinical significance. Pathol Res Pract. 215:1526162019. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Chen Q, Zhou L, Ma D, Hou J, Lin Y, Wu J
and Tao M: LncRNA GAS6-AS1 facilitates tumorigenesis and metastasis
of colorectal cancer by regulating TRIM14 through
miR-370-3p/miR-1296-5p and FUS. J Transl Med. 20:3562022.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Lu GH, Zhao HM, Liu ZY, Cao Q, Shao RD and
Sun G: LncRNA SAMD12-AS1 promotes the progression of gastric cancer
via DNMT1/p53 Axis. Arch Med Res. 52:683–691. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Macleod K: Tumor suppressor genes. Curr
Opin Genet Dev. 10:81–93. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Sherr CJ: Principles of tumor suppression.
Cell. 116:235–246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Sun W and Yang J: Functional mechanisms
for human tumor suppressors. J Cancer. 1:136–140. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Liu HT, Liu S, Liu L, Ma RR and Gao P:
EGR1-Mediated Transcription of lncRNA-HNF1A-AS1 promotes cell-cycle
progression in gastric cancer. Cancer Res. 78:5877–5890. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Zhang J, Cui K, Huang L, Yang F, Sun S,
Bian Z, Wang X, Li C, Yin Y, Huang S, et al: SLCO4A1-AS1 promotes
colorectal tumourigenesis by regulating Cdk2/c-Myc signalling. J
Biomed Sci. 29:42022. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Ni X, Ding Y, Yuan H, Shao J, Yan Y, Guo
R, Luan W and Xu M: Long non-coding RNA ZEB1-AS1 promotes colon
adenocarcinoma malignant progression via miR-455-3p/PAK2 axis. Cell
Prolif. 53:e127232020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Wu X, Cui F, Chen Y, Zhu Y and Liu F: Long
Non-Coding RNA LOXL1-AS1 enhances colorectal cancer proliferation,
migration and invasion through miR-708-5p/CD44-EGFR Axis. Onco
Targets Ther. 13:7615–7627. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Flecken T, Schmidt N, Hild S, Gostick E,
Drognitz O, Zeiser R, Schemmer P, Bruns H, Eiermann T, Price DA, et
al: Immunodominance and functional alterations of tumor-associated
antigen-specific CD8+ T-cell responses in hepatocellular carcinoma.
Hepatology. 59:1415–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Chow A, Perica K, Klebanoff CA and Wolchok
JD: Clinical implications of T cell exhaustion for cancer
immunotherapy. Nat Rev Clin Oncol. 19:775–790. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
He X and Xu C: Immune checkpoint signaling
and cancer immunotherapy. Cell Res. 30:660–669. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Pu Y and Ji Q: Tumor-Associated
macrophages regulate PD-1/PD-L1 immunosuppression. Front Immunol.
13:8745892022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor
immunity. Curr opin immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Fan F, Chen K, Lu X, Li A, Liu C and Wu B:
Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging
hsa-miR-194-5p induces immunosuppression in hepatocellular
carcinoma. Hepatol Int. 15:444–458. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Han Y, Liu D and Li L: PD-1/PD-L1 pathway:
Current researches in cancer. Am J Cancer Res. 10:727–742.
2020.PubMed/NCBI
|
|
129
|
Zhou Z, Liu Q, Zhang G, Mohammed D, Amadou
S, Tan G and Zhang X: HOXA11-AS1 Promotes PD-L1-Mediated immune
escape and metastasis of hypopharyngeal carcinoma by facilitating
PTBP1 and FOSL1 Association. Cancers (Basel). 14:36942022.
View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Chen YG, Satpathy AT and Chang HY: Gene
regulation in the immune system by long noncoding RNAs. Nat
immunol. 18:962–972. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Wu Y, Song Y, Wang R and Wang T: Molecular
mechanisms of tumor resistance to radiotherapy. Mol Cancer.
22:962023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Hou J, Zhang G, Wang X, Wang Y and Wang K:
Functions and mechanisms of lncRNA MALAT1 in cancer chemotherapy
resistance. Biomark Res. 11:232023. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Chen QN, Wei CC, Wang ZX and Sun M: Long
non-coding RNAs in anti-cancer drug resistance. Oncotarget.
8:1925–1936. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ni J, Bucci J, Malouf D, Knox M, Graham P
and Li Y: Exosomes in cancer radioresistance. Front Oncol.
9:8692019. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Zhou M, Dong J, Huang J, Ye W, Zheng Z,
Huang K, Pan Y, Cen J, Liang Y, Shu G, et al: Chitosan-Gelatin-EGCG
Nanoparticle-Meditated LncRNA TMEM44-AS1 Silencing to Activate the
P53 signaling pathway for the synergistic reversal of 5-FU
resistance in gastric cancer. Adv Sci (Weinh). 9:e21050772022.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Qu L, Chen Y, Zhang F and He L: The lncRNA
DLGAP1-AS1/miR-149-5p/TGFB2 axis contributes to colorectal cancer
progression and 5-FU resistance by regulating smad2 pathway. Mol
Ther Oncolytics. 20:607–624. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gui Z, Zhao Z, Sun Q, Shao G, Huang J,
Zhao W and Kuang Y: LncRNA FEZF1-AS1 promotes multi-drug resistance
of gastric cancer cells via upregulating ATG5. Front Cell Dev Biol.
9:7491292021. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Zou Y, Yao S, Chen X, Liu D, Wang J, Yuan
X, Rao J, Xiong H, Yu S, Yuan X, et al: LncRNA OIP5-AS1 regulates
radioresistance by targeting DYRK1A through miR-369-3p in
colorectal cancer cells. Eur J Cell Biol. 97:369–378. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Song L, Zhou Z, Gan Y, Li P, Xu Y, Zhang
Z, Luo F, Xu J, Zhou Q and Dai F: Long noncoding RNA OIP5-AS1
causes cisplatin resistance in osteosarcoma through inducing the
LPAATβ/PI3K/AKT/mTOR signaling pathway by sponging the miR-340-5p.
J Cell Biochem. 120:9656–9666. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Wu Q, Ma J, Wei J, Meng W, Wang Y and Shi
M: FOXD1-AS1 regulates FOXD1 translation and promotes gastric
cancer progression and chemoresistance by activating the
PI3K/AKT/mTOR pathway. Mol Oncol. 15:299–316. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Qi FF, Yang Y, Zhang H and Chen H: Long
non-coding RNAs: Key regulators in oxaliplatin resistance of
colorectal cancer. Biomed Pharmacother. 128:1103292020. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Shi CJ, Xue ZH, Zeng WQ, Deng LQ, Pang FX,
Zhang FW, Fu WM and Zhang JF: LncRNA-NEF suppressed oxaliplatin
resistance and epithelial-mesenchymal transition in colorectal
cancer through epigenetically inactivating MEK/ERK signaling.
Cancer Gene Ther. 30:855–865. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R,
Sun R, Liu J, Xiao Q, Li Y, et al: Downregulation of MEIS1 mediated
by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and
oxaliplatin resistance in colorectal cancer. Signal Transduct
Target. 7:872022. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Liang J, Tian XF and Yang W: Effects of
long non-coding RNA Opa-interacting protein 5 antisense RNA 1 on
colon cancer cell resistance to oxaliplatin and its regulation of
microRNA-137. World J Gastroenterol. 26:1474–1489. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Hui B, Lu C, Wang J, Xu Y, Yang Y, Ji H,
Li X, Xu L, Wang J, Tang W, et al: Engineered exosomes for
co-delivery of PGM5-AS1 and oxaliplatin to reverse drug resistance
in colon cancer. J Cell Physiol. 237:911–933. 2022. View Article : Google Scholar : PubMed/NCBI
|
